Role of chausath prahari pippali churna in bronchial asthma

Evaluate the efficacy of Chausath Prahari Pippali Churna in Disintegration of Pathogenesis of Tamaka Shwasa- Single Arm Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/052104

Enrollment

Registered

2023-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J452- Mild intermittent asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Mild to Moderate Bronchial Asthma acc. to NAEPP classification in age group of 18- 60 yrs.

Exclusion criteria

Exclusion criteria: Patient with Severe Bronchial Asthma acc. to NAEPP classification. Patients with Other comorbidity. Pregnant women and Lactating Mother. Patient with Known Hypersensitivity to Pippali.

Design outcomes

Primary

Measure	Time frame
Findings of the study will be beneficial in the Clinical management of Tamaka shwasa by establishing the Efficacy of Chausath Prahari Pippali ChurnaTimepoint: 45 days with follow-up on every 15 days.	—

Secondary

Measure	Time frame
The study will provide cost effective, safe drug with lesser side-effectsTimepoint: 12 months	—

Countries

India

Contacts

Public ContactDr Ashok Kumar Madan Singh

Chaudhary Brahm Prakash Ayurved Charak Sansthan

ashokdagar01@gmail.com9899867606

Outcome results